Gene | Breast tumor phenotype | Diagnosis <50 years | Diagnosis ≥50 to 70 years |
---|
% Carriers | % BCAC | LR | (95% CI) | % Carriers | % BCAC | LR | (95% CI) |
---|
BRCA1
| Triple-negative | 67.3 | 17.5 | 3.73 | (3.43-4.05) | 57.7 | 12.9 | 4.41 | (3.86-5.04) |
Not triple-negative | 32.7 | 82.5 | 0.40 | (0.37-0.44) | 42.3 | 87.1 | 0.49 | (0.42-0.56) |
 | 100% | 100% |  |  | 100% | 100% |  |  |
BRCA2
| Triple-negative | 13.0 | 17.5 | 0.72 | (0.59-0.87) | 23.5 | 12.9 | 1.79 | (1.42-2.24) |
Not triple-negative | 87.0 | 82.5 | 1.06 | (0.98-1.15) | 76.5 | 87.1 | 0.88 | (0.78-1.00) |
 | 100% | 100% |  |  | 100% | 100% |  |  |
- Analyses stratified by country, as described in the Methods section. Analysis included tumor phenotypes from 2,249 BRCA1 mutation carriers (1,788 < 50 years, 461 ≥ 50 years), 1,195 BRCA2 mutation carriers (859 < 50 years, 336 ≥ 50 years) and 19,178 BCAC cases with no report of positive BRCA1/2 mutation status (7,103 < 50 years, 12,075 ≥ 50 years). LR, likelihood ratio. Triple-negative phenotype defined as ER-negative, PR-negative, HER2-negative; not triple-negative; all other combinations, with status measured for all three markers.